Skip to main content

Table 2 Prognostic factors for overall survival

From: Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma

Factor 5-year OS (%) Univariate analysis Multivariate analysis
P-value HR (95 % CI)
Treatment option    
  Complete TACE 50   
  TACE + Curative Tx 58 0.843 1.100 (0.521–2.324)
  TACE + SABR 53 0.493 1.207 (0.573–2.545)
  TACE + Non-curative Tx 28 0.010 2.421 (1.248–4.498)
BCLC stage    
  0 54   
  A 42 0.139 -
CTP score    
  5 48   
  6 33 0.128 1.037 (0.622–1.729)
  7 29 0.013 2.229 (1.147–4.332)
Tumor size (cm)    
  0.1–3.0 49   
  3.1–10.0 32 0.008 -
  1. Abbreviations: OS overall survival, TACE transcatheter arterial chemoembolization, Tx treatment, SABR stereotactic ablative radiotherapy, BCLC Barcelona Clinic Liver Cancer, CTP Child-Turcotte-Pugh